DMX-200 COVID-19 Study Opens More Sites in Europe and UK
Filed with ASX · · 3 pages · English
• 167 patients with COVID-19 pneumonia enrolled across the ACE2 RAS modulation REMAP-CAP study domain in Europe o 43 sites currently recruiting domain in UK, Netherlands, and Italy • DMX-200 has regulatory study approval in both UK and Netherlands, with additional study sites anticipated to recruit DMX-200 patients in Italy following submission in July 2021 • DMX-200 available at clinical sites fo
Story so far
Earlier from Dimerix
- FDA Confirms Phase 3 Study Design in FSGS Kidney Disease
- Dimerix Receives Innovation Passport and ILAP Designation
- Dimerix Confirms Phase 3 FSGS Study Design With EMA
- DMX-200 Remains Eligible for Accelerated Approval
- COVID-19 Study Recruits Multiple Patients in Europe
Later from Dimerix
- Successful $20m Placement to Fund Phase 3 Trials
- Response to ASX Query
- SPP and Options Prospectus
- Phase 3 Study in FSGS Kidney Patients Commences
- DMX-200 CLARITY COVID-19 Study Approval in India
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix